Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Daiichi Sankyo Company, Limited (DSKYF)

26.00
-0.05
(-0.19%)
At close: May 2 at 3:47:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DSKYF

Recent News: DSKYF

View More
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK or DSNKY: Which Is the Better Value Stock Right Now?
Zacks yesterday
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial
Clinical Trials Arena 12 days ago
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
Benzinga 12 days ago
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer
Business Wire 13 days ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
Zacks 17 days ago
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
The Wall Street Journal 24 days ago
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Business Wire 26 days ago
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers
Pharmaceutical Technology 29 days ago
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy
Business Wire 30 days ago
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
Zacks last month
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
Business Wire last month
View More

Related Tickers

4AB.BE AbbVie Inc
175.40
+2.45%
 
MRK.NE Merck & Co., Inc.
19.13
+0.10%
 
JNJ.NE JOHNSON & JOHNSON CDR (CAD HEDG
20.59
+1.18%
 
RHHBF Roche Holding AG
345.35
+16.67%
 
GLAXF GSK plc
18.95
0.00%
 
AZNCF AstraZeneca PLC
146.74
0.00%
 
PFE.NE Pfizer Inc.
11.12
+0.91%
 
LLY.NE Eli Lilly and Company
30.45
+3.85%
 
BAYRY Bayer Aktiengesellschaft
6.74
-0.15%
 
NONOF Novo Nordisk A/S
68.40
-2.15%